Mast cell chymase degrades apoe and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 22, Issue 9, 2002, Pages 1475-1481

  Lee, Miriam ^a,c   Calabresi, Laura ^b   Chiesa, Giulia ^b   Franceschini, Guido ^b   Kovanen, Petri T ^a  

^a WIHURI RESEARCH INSTITUTE   (Finland)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF HAVANA   (Cuba)

Author keywords

Apolipoprotein A I knockout mice; Chymase; Mast cells; Reconstituted HDL; Reverse cholesterol transport

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; APOLIPOPROTEIN E; CHYMASE; HIGH DENSITY LIPOPROTEIN;

ANIMAL CELL; ARTICLE; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; FOAM CELL; KNOCKOUT MOUSE; LIPOPROTEIN BLOOD LEVEL; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; QUANTITATIVE ANALYSIS;

ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; APOLIPOPROTEINS E; BIOLOGICAL TRANSPORT, ACTIVE; CHOLESTEROL; CHYMASES; FEMALE; FOAM CELLS; HUMANS; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOSOMES; MACROPHAGES, PERITONEAL; MALE; MAST CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOSPHATIDYLCHOLINES; PROTEINS; RECOMBINANT FUSION PROTEINS; SECRETORY VESICLES; SERINE ENDOPEPTIDASES;

EID: 0036738407     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000029782.84357.68     Document Type: Article

References (37)

1. Role of mast cells in atherosclerosis
2. Mast cell-mediated inhibition of reverse cholesterol transport
3. Chymase in exocytosed rat mast cell granules effectively proteolyzes apolipoprotein AI-containing lipoproteins, so reducing the cholesterol efflux-inducing ability of serum and aortic intimal fluid
4. 1LpA-I and LpA-IV by mast cell chymase reduces the cholesterol efflux ability promoted by plasma
5. Identification of domains in apoA-I susceptible to proteolysis by mast cell chymase: Implications for HDL function
6. Apolipoprotein A-I: Structure-function relationships
7. Cell cholesterol efflux: Integration of old and new observations provides new insights
8. Release of cellular cholesterol: Molecular mechanism for cholesterol homeostasis in cells and in the body
9. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway
10. Cholesterol efflux potential of sera from mice expressing human cholesteryl ester transfer protein and/or human apolipoprotein AI
11. Human apolipoproteins A-I and A-II in cell cholesterol efflux: Studies with transgenic mice
12. Role of HDL phospholipid in efflux of cell cholesterol to whole serum: Studies with human apoA-I transgenic rats
13. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV
14. Transgenic animals with altered high-density lipoprotein composition and functions
15. Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I
16. Soluble heparin proteoglycans released from stimulated mast cells induce uptake of low density lipoproteins by macrophages via scavenger receptor-mediated phagocytosis
17. Low density lipoprotein degradation by secretory granules of rat mast cells
18. Chymase bound to heparin is resistant to its natural inhibitors and capable of proteolyzing high density lipoproteins in aortic intimal fluid
19. The molecular structure of apolipoprotein A-II modulates the capacity of HDL to promote cell cholesterol efflux
20. Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions
21. Nondenaturing polyacrylamide gradient gel electrophoresis
22. A new enzymatic method for determination of serum choline-containing phospholipids
23. Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts
24. Receptor-dependent hydrolysis of cholesteryl esters contained in plasma low density lipoprotein
25. Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice
26. ApoA-I knockout mice: Characterization of HDL metabolism in homozygotes and identification of a post-RNA mechanism of apoA-I up-regulation in heterozygotes
27. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice
28. Expression of human apolipoprotein A-II and its effect on high density lipoproteins in transgenic mice
29. Modification of the cholesterol efflux properties of human serum by enrichment with phospholipid
30. Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport
31. Apolipoprotein-mediated cellular cholesterol/phospholipid efflux and plasma high density lipoprotein level in mice
32. Reverse cholesterol transport in plasma of patients with different forms of familial HDL deficiency
33. Lipoproteins containing apolipoprotein A-IV but not apolipoprotein A-I take up and esterify cell-derived cholesterol in plasma
34. A plasma lipoprotein containing only apolipoprotein E and with gamma-mobility on electrophoresis releases cholesterol from cells
35. Atherosclerosis in the mouse: A decade of experience
36. Mouse plasma trypsin inhibitors. Isolation and characterization of alpha-1-antitrypsin and contrapsin, a novel trypsin inhibitor
37. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice